Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Menu

Search BMS Clinical Trials
BMS Recruiting Study icon

Recruiting

Trial ID CA088-1005  |   NCT06121843

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

Summary

  • Phase 1
  • Male and Female Gender icon
  • 18+
    Age Range
  • 19
    Locations
  • BMS Recruiting Study icon
    Recruiting

Overview

The purpose of this study is to establish a safe and tolerable dose of BMS-986393 in combinations with alnuctamab, mezigdomide, and iberdomide in participants with relapsed and/or refractory multiple myeloma (RRMM).

print Print
email Email

Nearest Recruiting Site

Key Eligibility Criteria

Inclusion Criteria

Inclusion Criteria Icon img
:
  • History of relapsed and/or refractory multiple myeloma (RRMM) treated with at least 3 (Part 1 and Part 2) or at least 1 but not greater than 3 prior anti-myeloma treatment regimens (Part 2)
    1. Measurable multiple myeloma (MM)
      1. Eastern Cooperative Oncology Group performance status of 0-1

        Exclusion Criteria

        Exclusion Criteria Icon
        :
        • Condition that confounds the ability to interpret data from the study
          1. Known active or history of central nervous system (CNS) involvement of MM Note: Other protocol-defined inclusion/exclusion criteria apply
            Additional Information *

            Treatment Options

            Study Arms

            ASSIGNED INTERVENTION

            Study Arms

            Experimental: Arm A: BMS-986393 + Alnuctamab

            ASSIGNED INTERVENTION
            • Drug: BMS-986393, Alnuctamab

            Study Arms

            Experimental: Arm B: BMS-986393 + Mezigdomide

            ASSIGNED INTERVENTION
            • Drug: BMS-986393, Mezigdomide

            Study Arms

            Experimental: Arm C: BMS-986393 + Iberdomide

            ASSIGNED INTERVENTION
            • Drug: BMS-986393, Iberdomide
            Take the first step to see if you Match to a Clinical Trial – Check Your Eligibility
            Check Your Eligibility
            Answer some questions about Your health to see if you may match to this trial
            Match to a Trial
            If you are a match, click on the study to see the list of study site locations
            Select a Study Site Location
            Select a study site location that is convenient for you
            Register
            Provide your contact details for the study site to connect with you.

            Help us enhance your website experience! Share your feedback with our team at BMS Clinical Trials to improve yours and others’ experience. Thank you